Hari V. Kalluri

Tilavonemab in early Alzheimer’s disease: results from a phase 2, randomized, double-blind study

Hana Florian, Deli Wang, Steven E. Arnold et al. · Brain · 2023 · 131 citations · Full text

Medicine, Neurology, Pharmacotherapy +17

An evidence-based recommendation to increase the dosing frequency of buprenorphine during pregnancy

Steve N. Caritis, Jaime R. Bastian, Hongfei Zhang et al. · American Journal of Obstetrics and Gynecology · 2017 · 65 citations · Full text

Medicine, Obstetrics, Pharmacology +11

Glecaprevir–pibrentasvir to treat chronic hepatitis C virus infection in Asia: two multicentre, phase 3 studies—a randomised, double-blind study (VOYAGE-1) and an open-label, single-arm study (VOYAGE-2)

Lai Wei, Guiqiang Wang, Negar N. Alami et al. · ˜The œLancet. Gastroenterology & hepatology · 2020 · 54 citations

Pharmacy, Infectious Diseases, Pharmacotherapy +14

Gestational changes in buprenorphine exposure: A physiologically‐based pharmacokinetic analysis

Hongfei Zhang, Hari V. Kalluri, Jaime R. Bastian et al. · British Journal of Clinical Pharmacology · 2018 · 37 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +17

A physiologically based pharmacokinetic modelling approach to predict buprenorphine pharmacokinetics following intravenous and sublingual administration

Hari V. Kalluri, Hongfei Zhang, Steve N. Caritis et al. · British Journal of Clinical Pharmacology · 2017 · 30 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +13